|
1
|
Davies L and Welch HG: Current thyroid
cancer trends in the United States. JAMA Otolaryngol Head Neck
Surg. 140:317–322. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Colonna M, Uhry Z, Guizard AV, Delafosse
P, Schvartz C, Belot A and Grosclaude P; FRANCIM network: Recent
trends in incidence, geographical distribution, and survival of
papillary thyroid cancer in France. Cancer Epidemiol. 39:511–518.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Siegel RL, Miller KD and Jemal A: Cancer
Statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
McLeod DS, Sawka AM and Cooper DS:
Controversies in primary treatment of low-risk papillary thyroid
cancer. Lancet. 381:1046–1057. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
La Vecchia C, Malvezzi M, Bosetti C,
Garavello W, Bertuccio P, Levi F and Negri E: Thyroid cancer
mortality and incidence: A global overview. Int J Cancer.
136:2187–2195. 2015. View Article : Google Scholar
|
|
6
|
Xing M, Alzahrani AS, Carson KA, Shong YK,
Kim TY, Viola D, Elisei R, Bendlová B, Yip L, Mian C, et al:
Association between BRAF V600E mutation and recurrence of papillary
thyroid cancer. J Clin Oncol. 33:42–50. 2015. View Article : Google Scholar :
|
|
7
|
Grogan RH, Kaplan SP, Cao H, Weiss RE,
Degroot LJ, Simon CA, Embia OM, Angelos P, Kaplan EL and Schechter
RB: A study of recurrence and death from papillary thyroid cancer
with 27 years of median follow-up. Surgery. 154:1436–1446;
discussion 1446–1447. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bartosch C, Monteiro-Reis S, Almeida-Rios
D, Vieira R, Castro A, Moutinho M, Rodrigues M, Graça I, Lopes JM
and Jerónimo C: Assessing sirtuin expression in endometrial
carcinoma and non-neoplastic endometrium. Oncotarget. 7:1144–1154.
2016.
|
|
9
|
Mouchiroud L, Houtkooper RH, Moullan N,
Katsyuba E, Ryu D, Cantó C, Mottis A, Jo YS, Viswanathan M,
Schoonjans K, et al: The NAD(+)/Sirtuin pathway modulates longevity
through activation of mitochondrial UPR and FOXO signaling. Cell.
154:430–441. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lai CC, Lin PM, Lin SF, Hsu CH, Lin HC, Hu
ML, Hsu CM and Yang MY: Altered expression of SIRT gene family in
head and neck squamous cell carcinoma. Tumour Biol. 34:1847–1854.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang X, Khan S, Jiang H, Antonyak MA,
Chen X, Spiegelman NA, Shrimp JH, Cerione RA and Lin H: Identifying
the functional contribution of the defatty-acylase activity of
SIRT6. Nat Chem Biol. 12:614–620. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Toiber D, Erdel F, Bouazoune K, Silberman
DM, Zhong L, Mulligan P, Sebastian C, Cosentino C, Martinez-Pastor
B, Giacosa S, et al: SIRT6 recruits SNF2H to DNA break sites,
preventing genomic instability through chromatin remodeling. Mol
Cell. 51:454–468. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang WW, Zeng Y, Wu B, Deiters A and Liu
WR: A chemical biology approach to reveal Sirt6-targeted Histone H3
sites in nucleosomes. ACS Chem Biol. 11:1973–1981. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kugel S, Sebastián C, Fitamant J, Ross KN,
Saha SK, Jain E, Gladden A, Arora KS, Kato Y, Rivera MN, et al:
SIRT6 Suppresses Pancreatic Cancer through Control of Lin28b. Cell.
165:1401–1415. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Marquardt JU, Fischer K, Baus K, Kashyap
A, Ma S, Krupp M, Linke M, Teufel A, Zechner U, Strand D, et al:
Sirtuin-6-dependent genetic and epigenetic alterations are
associated with poor clinical outcome in hepatocellular carcinoma
patients. Hepatology. 58:1054–1064. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Elhanati S, Ben-Hamo R, Kanfi Y, Varvak A,
Glazz R, Lerrer B, Efroni S and Cohen HY: Reciprocal regulation
between SIRT6 and miR-122 controls liver metabolism and predicts
hepatocarcinoma prognosis. Cell Rep. 14:234–242. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Thirumurthi U, Shen J, Xia W, LaBaff AM,
Wei Y, Li CW, Chang WC, Chen CH, Lin HK, Yu D, et al: MDM2-mediated
degradation of SIRT6 phosphorylated by AKT1 promotes tumorigenesis
and trastuzumab resistance in breast cancer. Sci Signal.
7:ra712014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Khongkow M, Olmos Y, Gong C, Gomes AR,
Monteiro LJ, Yagüe E, Cavaco TB, Khongkow P, Man EP, Laohasinnarong
S, et al: SIRT6 modulates paclitaxel and epirubicin resistance and
survival in breast cancer. Carcinogenesis. 34:1476–1486. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ming M, Han W, Zhao B, Sundaresan NR, Deng
CX, Gupta MP and He YY: SIRT6 promotes COX-2 expression and acts as
an oncogene in skin cancer. Cancer Res. 74:5925–5933. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Xie Q, Wong AS and Xia W: SIRT6 induces
EMT and promotes cancer cell invasion and migration in prostate
cancer. In: Proceedings of the 105th Annual Meeting of the American
Association for Cancer Research. Cancer Res. 74(Suppl 19): Abst
1151. 2014. View Article : Google Scholar
|
|
21
|
Kugel S, Feldman JL, Klein MA, Silberman
DM, Sebastián C, Mermel C, Dobersch S, Clark AR, Getz G, Denu JM,
et al: Identification of and molecular basis for SIRT6
loss-of-lunction point mutations in cancer. Cell Rep. 13:479–488.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sebastián C, Zwaans BM, Silberman DM,
Gymrek M, Goren A, Zhong L, Ram O, Truelove J, Guimaraes AR, Toiber
D, et al: The histone deacetylase SIRT6 is a tumor suppressor that
controls cancer metabolism. Cell. 151:1185–1199. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bai L, Lin G, Sun L, Liu Y, Huang X, Cao
C, Guo Y and Xie C: Upregulation of SIRT6 predicts poor prognosis
and promotes metastasis of non-small cell lung cancer via the
ERK1/2/MMP9 pathway. Oncotarget. 7:40377–40386. 2016.PubMed/NCBI
|
|
24
|
Liu X, Qu S, Liu R, Sheng C, Shi X, Zhu G,
Murugan AK, Guan H, Yu H, Wang Y, et al: TERT promoter mutations
and their association with BRAF V600E mutation and aggressive
clinicopathological characteristics of thyroid cancer. J Clin
Endocrinol Metab. 99:E1130–E1136. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Howell GM, Nikiforova MN, Carty SE,
Armstrong MJ, Hodak SP, Stang MT, McCoy KL, Nikiforov YE and Yip L:
BRAF V600E mutation independently predicts central compartment
lymph node metastasis in patients with papillary thyroid cancer.
Ann Surg Oncol. 20:47–52. 2013. View Article : Google Scholar
|
|
26
|
Becker TM, Boyd SC, Mijatov B,
Gowrishankar K, Snoyman S, Pupo GM, Scolyer RA, Mann GJ, Kefford
RF, Zhang XD, et al: Mutant B-RAF-Mcl-1 survival signaling depends
on the STAT3 transcription factor. Oncogene. 33:1158–1166. 2014.
View Article : Google Scholar
|
|
27
|
Kawakami H, Huang S, Pal K, Dutta SK,
Mukhopadhyay D and Sinicrope FA: Mutant BRAF upregulates MCL-1 to
confer apoptosis resistance that is reversed by MCL-1 antagonism
and cobimetinib in colorectal cancer. Mol Cancer Ther.
15:3015–3027. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Liu D, Liu J, Lin B, Liu S, Hou R, Hao Y,
Liu Q, Zhang S and Iwamori M: Lewis y regulate cell cycle related
factors in ovarian carcinoma cell RMG-I in vitro via ERK and Akt
signaling pathways. Int J Mol Sci. 13:828–839. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
He K, Chen D, Ruan H, Li X, Tong J, Xu X,
Zhang L and Yu J: BRAFV600E-dependent Mcl-1 stabilization leads to
everolimus resistance in colon cancer cells. Oncotarget.
7:47699–47710. 2016.PubMed/NCBI
|
|
30
|
Gao M, Kong Q, Hua H, Yin Y, Wang J, Luo T
and Jiang Y: AMPK-mediated up-regulation of mTORC2 and MCL-1
compromises the anti-cancer effects of aspirin. Oncotarget.
7:16349–16361. 2016.PubMed/NCBI
|
|
31
|
Feng XX, Luo J, Liu M, Yan W, Zhou ZZ, Xia
YJ, Tu W, Li PY, Feng ZH and Tian DA: Sirtuin 6 promotes
transforming growth factor-β1/H2O2/HOCl-mediated enhancement of
hepatocellular carcinoma cell tumorigenicity by suppressing
cellular senescence. Cancer Sci. 106:559–566. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kawahara TL, Michishita E, Adler AS,
Damian M, Berber E, Lin M, McCord RA, Ongaigui KC, Boxer LD, Chang
HY, et al: SIRT6 links histone H3 lysine 9 deacetylation to
NF-kappaB-dependent gene expression and organismal life span. Cell.
136:62–74. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Cheng MY, Cheng YW, Yan J, Hu XQ, Zhang H,
Wang ZR, Yin Q and Cheng W: SIRT6 suppresses mitochondrial defects
and cell death via the NF-κB pathway in myocardial
hypoxia/reoxygenation induced injury. Am J Transl Res. 8:5005–5015.
2016.
|
